The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.
Recurrence treatment
Thymic carcinoma
Thymic neuroendocrine carcinoma
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
04
05
2020
accepted:
28
07
2020
pubmed:
11
8
2020
medline:
16
9
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
There are few data available on the outcomes of postoperative recurrent thymic carcinoma (TC) and thymic neuroendocrine carcinoma (TNEC). The aim of this study is to evaluate the treatment and survival in patients with recurrent TC and TNEC after undergoing surgical resection. A retrospective chart review was performed using our multicenter database to identify patients with a postoperative recurrence of TC and TNEC from 1995 to 2018. The clinicopathological factors were reviewed and the survival outcomes were analyzed. Sixty patients were identified among 152 patients who underwent resection of TC and TNEC. The median follow-up period from the first recurrence was 14.8 months (range 0-144). The 5-year post-recurrence survival was 23% for the whole cohort. According to a univariable analysis, advanced stage [hazard ratio (HR) 2.81, 95% confidence interval (CI) 1.09-9.54], interval between primary surgery and recurrence (HR 0.97, 95% CI 0.95-0.99), any treatment for recurrence (HR: 0.27, 95% CI 0.13-0.58) and chemotherapy for recurrence (HR: 0.46, 95% CI 0.22-0.95) were significant factors related to post-recurrence survival. Chemotherapy rather than surgery appears to be the mainstay treatment for managing patients with postoperative recurrent TC and TNEC and it may also be considered in multidisciplinary management. Further studies with a larger sample size are required to confirm our findings.
Identifiants
pubmed: 32776294
doi: 10.1007/s00595-020-02102-7
pii: 10.1007/s00595-020-02102-7
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-510Références
Cardillo G, Rea F, Lucchi M, Paul MA, Margaritora S, Carleo F, et al. Primary neuroendocrine tumors of the thymus: a multicenter experience of 35 patients. Ann Thorac Surg. 2012;94(1):241–5 discussion 5–6.
doi: 10.1016/j.athoracsur.2012.03.062
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, et al. Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the international thymic malignancy interest group and the European Society of Thoracic Surgeons databases. J Thorac Cardiovasc Surg. 2015;149(1):103–9.e2.
doi: 10.1016/j.jtcvs.2014.08.061
Ruffini E, Guerrera F, Brunelli A, Passani S, Pellicano D, Thomas P, et al. Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours. Eur J Cardiothorac Surg. 2019;55(4):601–9.
doi: 10.1093/ejcts/ezy448
Committee for Scientific Affairs TJAfTS, Shimizu H, Endo S, Natsugoe S, Doki Y, Hirata Y, et al. Thoracic and cardiovascular surgery in Japan in 2016: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2019;67(4):377–411.
doi: 10.1007/s11748-019-01068-9
Hishida T, Nomura S, Yano M, Asamura H, Yamashita M, Ohde Y, et al. Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese nationwide database study. Eur J Cardiothorac Surg. 2016;49(3):835–41.
doi: 10.1093/ejcts/ezv239
Filosso PL, Yao X, Ruffini E, Ahmad U, Antonicelli A, Huang J, et al. Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the international thymic malignancy interest group. Eur J Cardiothorac Surg. 2016;50(4):766–71.
doi: 10.1093/ejcts/ezw107
Park IK, Kim YT, Jeon JH, Kim HS, Hwang Y, Seong YW, et al. Importance of lymph node dissection in thymic carcinoma. Ann Thorac Surg. 2013;96(3):1025–32 discussion 32.
doi: 10.1016/j.athoracsur.2013.04.057
Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. Thymic carcinoma: a cohort study of patients from the European Society of Thoracic Surgeons database. J Thorac Oncol. 2014;9(4):541–8.
doi: 10.1097/JTO.0000000000000128
Hamaji M, Allen MS, Cassivi SD, Nichols FC 3rd, Wigle DA, Deschamps C, et al. The role of surgical management in recurrent thymic tumors. Ann Thorac Surg. 2012;94(1):247–54 discussion 54.
doi: 10.1016/j.athoracsur.2012.02.092
Fiorelli A, D’Andrilli A, Vanni C, Cascone R, Anile M, Diso D, et al. Iterative surgical treatment for repeated recurrences after complete resection of thymic tumors. Ann Thorac Surg. 2017;103(2):422–31.
doi: 10.1016/j.athoracsur.2016.08.086
Hamaji M, Shah RM, Ali SO, Bettenhausen A, Lee HS, Burt BM. A meta-analysis of postoperative radiotherapy for thymic carcinoma. Ann Thorac Surg. 2017;103(5):1668–75.
doi: 10.1016/j.athoracsur.2016.12.042
Miyata R, Hamaji M, Omasa M, Nakagawa T, Sumitomo R, Huang CL, et al. Survival outcomes after minimally invasive thymectomy for early-stage thymic carcinoma. Surg Today. 2019;49(4):357–60.
doi: 10.1007/s00595-018-1740-x
Filosso PL, Guerrera F, Rendina AE, Bora G, Ruffini E, Novero D, et al. Outcome of surgically resected thymic carcinoma: a multicenter experience. Lung Cancer. 2014;83(2):205–10.
doi: 10.1016/j.lungcan.2013.11.015
Zhao Y, Gu H, Fan L, Han K, Yang J, Zhao H. Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients. Eur J Cardiothorac Surg. 2017;52(1):33–8.
doi: 10.1093/ejcts/ezx037
Omasa M, Date H, Sozu T, Sato T, Nagai K, Yokoi K, et al. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study. Cancer. 2015;121(7):1008–166.
doi: 10.1002/cncr.29166
Mizuno T, Okumura M, Asamura H, Yoshida K, Niwa H, Kondo K, et al. Surgical management of recurrent thymic epithelial tumors: a retrospective analysis based on the Japanese nationwide database. J Thorac Oncol. 2015;10(1):199–205.
doi: 10.1097/JTO.0000000000000378
NCCN clinical practice guidelines in Oncology. Thymomas and Thymic Carcinomas, Available at NCCN, www.nccn.org/professionals/physician_gls/pdf/thymic_blocks.pdf Accessed Apr 14, 2017.
Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v40–55.
doi: 10.1093/annonc/mdv277
JLCS clinical practice guidelines in Thymic Epithelial Tumors, Available at JLCS, www.haigan.gr.jp/guideline/2019/3/2/190302030100.html#3-2 Accessed Feb 18, 2020.
Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 2011;29(15):2060–5.
doi: 10.1200/JCO.2010.32.9607
Furugen M, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol. 2011;41(8):1013–6.
doi: 10.1093/jjco/hyr089
Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, et al. A prospective phase ii study of cisplatin and cremophor EL-free paclitaxel (Genexol-PM) in patients with unresectable thymic epithelial tumors. J Thorac Oncol. 2015;10(12):1800–6.
doi: 10.1097/JTO.0000000000000692
Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer. 2010;67(2):194–7.
doi: 10.1016/j.lungcan.2009.03.031
Hirai F, Yamanaka T, Taguchi K, Daga H, Ono A, Tanaka K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. Ann Oncol. 2015;26(2):363–8.
doi: 10.1093/annonc/mdu541
Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, et al. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan lung cancer group study 0803. J Thorac Oncol. 2014;9(12):1805–9.
doi: 10.1097/JTO.0000000000000362
Moore RR, Nagai H, Miller RA, Hardisty JF, Allison N, Shockley KR, et al. Comparative incidences and biological outcomes for thymoma in various rat strains in national toxicology program studies. Toxicol Pathol. 2019;47(7):833–41.
doi: 10.1177/0192623319863119
Lee SS, Park WY, Chi JG, Seo JW, Kim JI, Kim CW, et al. Thymic epithelial tumor progression in an SV40T transgenic mouse model. Cortical thymoma-thymic carcinoma sequence Virchows Arch. 1998;432(1):33–42.
pubmed: 9463585
Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP, et al. Systemic treatments for thymoma and thymic carcinoma: a systematic review. Lung Cancer. 2018;126:25–31.
doi: 10.1016/j.lungcan.2018.10.018
Hirai F, Toyozawa R, Nosaki K, Seto T. Are anthracycline-based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma? J Thorac Oncol. 2016;11:115–21.
doi: 10.1016/j.jtho.2015.09.007
Okumura M, Shiono H, Inoue M, Tanaka H, Yoon HE, Nakagawa K, et al. Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system. J Surg Oncol. 2007;95(1):40–4.
doi: 10.1002/jso.20671
Yen YT, Lai WW, Chang KW, Chang KC, Lee SC, Lin SH, et al. Factors predicting recurrence and postrecurrence survival in completely resected thymic carcinoma. Ann Thorac Surg. 2014;97(4):1169–75.
doi: 10.1016/j.athoracsur.2013.12.024